Global Radioligand Therapy Market

Report ID : 1281 | Published : 2022-06-22 | Pages: | Format: PDF/EXCEL

The Global Radioligand Therapy Market is estimated to reach over USD 12.53 billion by 2030, exhibiting a CAGR of 6.4% during the forecast period. 

Radioligand therapy (RLT) is a cancer treatment strategy that uses targeted medicines. Radioactive isotopes, especially beta-emitters like lutetium-177, are used to identify ligands. It can yield a high rate of long-term tumor remission and stability. It is a systemic therapy used to treat metastasized disease. Radiopharmaceuticals bind to a tumor target in radioligand therapy. An increase in cancer prevalence around the world is expected to drive market growth over the forecast period. As radiopharmaceuticals and radiation are very successful, they are increasingly in demand for malignancies, fueling the expansion of the radioligand therapy market. The expansion of pharmaceutical companies' footprint is also expected to fuel the global radioligand therapy market.

Furthermore, the global radioligand therapy market is likely to be propelled by research and development of radioligand therapy candidates to treat a wide range of cancer types. With the growing demand for radiotherapy and government financing in this field, market participants are focusing more on the research, approval, and launch of worldly goods, particularly medications based on radioligands, which is propelling the market forward. However, over the next few years, the rapid development of radiological pharmaceuticals for targeted diagnosis and therapy is predicted to raise the radioligand therapy market sales value.

However, one of the key challenges limiting the implementation of radioligand therapy in emerging and developing economies is a lack of suitable healthcare infrastructure due to limited healthcare expenditure. Only a few healthcare facilities in undeveloped and emerging nations are now equipped to use sophisticated radiotherapy for cancer treatment. As a result, despite great demand, the number of radioligand therapy procedures is being limited. In addition, the growth of the radioligand therapy market is limited by high treatment costs and complicated reimbursement processes.

Market Segmentation:

The Radioligand Therapy market is segmented on the basis of biomarkers, indications and products. Based on a biomarker, the market is segmented as Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading and Cytochrome P450 17A1 Inhibitor. By indications, the market is segmented into Prostate Cancer, Neuroendocrine Tumor (NETs) and Others Indications. Based on products, the market is segmented into Approved Products and Potential Pipelines.

Based on indication, the prostate cancer segment is accounted as a major contributor in the Radioligand Therapy market.

By indication, the market is segmented into Prostate Cancer, Neuroendocrine Tumor (NETs) and Others Indications. The prostate cancer segment is anticipated to lead due to the increased geriatric population, increased prevalence of prostate cancer, increased public awareness of prostate cancer treatment, increased R&D expenditure, and availability of innovative prostate cancer medicines. Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland increase and expand uncontrollably. Prostate cancer is the sixth leading cause of death in men and the eleventh leading cause of death from any disease. Numerous prostate cancers are slow-growing and restricted to the prostate gland, where they are unlikely to cause major damage. Radioligand binds to prostate-specific membrane antigen and is used to treat prostate cancer (PSMA). In prostate cancer, prostate-specific membrane antigens (PSMA) are over-expressed.

The approved products segment witnessed growth at a rapid rate.

The market is divided into approved products and potential pipelines based on product. The category of approved products accounts for a significant share of the industry. This is mostly due to the availability of a diverse variety of products, as well as the introduction of new and improved FDA-authorized and more effective techniques such as beta-emitters lutetium 177, prostate-specific membrane antigen (PSMA), and other approved cancer treatments. On the other hand, the potential pipeline segment is expected to grow at a substantial rate as leading companies in the radioligand therapy industry are making strategic acquisitions to Thus, the market is projected to be propelled during the forecast period by the approval and commercialization of potential pipeline products in the near future.

The North America Radioligand Therapy market holds a significant revenue share in the region.

North America is expected to dominate the radioligand therapy market over the forecast period. North America is the main market for radioligand therapy (RLT), owing to a high rate of product acceptance following FDA approval. With well-established market players and regular product launches in the region, clinical research activity and new product launches are increasing, hence driving the market growth in this region. Furthermore, increased awareness of radioligand therapy and an increase in the number of cancer patients in the United States are projected to fuel the market in the area. The increase is ascribed to government initiatives to improve chronic disease treatment and the number of specialized cancer hospitals and research institutions. As a result, the growing number of government programmes aimed at improving oncologic practices expands the market for radioligand therapy in this region. Manufacturers are focusing on forming partnerships with laboratories for radioligand treatment candidate research and development, which is expected to push the market. However, the European market is expected to grow at a significant rate as the Europe's governments offer extensive reimbursement programmes. Additionally, growth in research laboratories, an increase in cancer prevalence, and an increase in government funding are expected to boost the market in the area during the projection period.

Competitive Landscape

Some of the major key players in the Radioligand Therapy market are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc. (Progenics Pharmaceuticals), Curium Pharma, Precirix, Radio Medix and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Radioligand Therapy Market Snapshot

Chapter 4. Global Radioligand Therapy Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis

5.1. By Biomarker, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Biomarker:

5.2.1. Prostate-Specific Membrane Antigen

5.2.2. Ki 67 Expression and Grading

5.2.3. Cytochrome P450 17A1 Inhibitor

Chapter 6. Market Segmentation 2: By Products Estimates & Trend Analysis

6.1. By Indications & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

6.2.1. Prostate Cancer

6.2.2. Neuroendocrine Tumor (NETs)

6.2.3. Others Indications

Chapter 7. Market Segmentation 3: By Indications Estimates & Trend Analysis

7.1. By Products & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

7.2.1. Approved Products

7.2.1.1. Lutathera

7.2.1.2.  Zytiga

7.2.1.3.  Xtandi

7.2.1.4.  Xofigo

7.2.2. Potential Pipeline

Chapter 8. Radioligand Therapy Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Biomarker, 2019-2030

8.1.2. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Indications, 2019-2030

8.1.3. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

8.1.4. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

8.2. Europe

8.2.1. Europe Radioligand Therapy Market revenue (US$ Million) By Biomarker, 2019-2030

8.2.2. Europe Radioligand Therapy Market revenue (US$ Million) By Indications, 2019-2030

8.2.3. Europe Radioligand Therapy Market revenue (US$ Million) By Products, 2019-2030

8.2.4. Europe Radioligand Therapy Market revenue (US$ Million) by country, 2019-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Biomarker, 2019-2030

8.3.2. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Indications, 2019-2030

8.3.3. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Products, 2019-2030

8.3.4. Asia Pacific Radioligand Therapy Market revenue (US$ Million) by country, 2019-2030

8.4. Latin America

8.4.1. Latin America Radioligand Therapy Market revenue (US$ Million) By Biomarker, (US$ Million) 2019-2030

8.4.2. Latin America Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2019-2030

8.4.3. Latin America Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

8.4.4. Latin America Radioligand Therapy Market revenue (US$ Million) by country, 2019-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Biomarker, (US$ Million) 2019-2030

8.5.2. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2019-2030

8.5.3. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

8.5.4. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) by country, 2019-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Johnson & Johnson Services, Inc.

9.2.2. Pfizer Inc.

9.2.3. Amneal Pharmaceuticals LLC

9.2.4. Novartis International AG

9.2.5. POINT Biopharma Global Inc

9.2.6. Fusion Pharma

9.2.7. Clovis Oncology

9.2.8. Telix Pharmaceuticals

9.2.9. Lantheus Holdings, Inc. (Progenics Pharmaceuticals)

9.2.10. Bayer AG

9.2.11. Molecular Partners

9.2.12. ITM Isotope Technologies Munich SE

9.2.13. Curium Pharma

9.2.14. Precirix

9.2.15. Radio Medix

9.2.16. Other Prominent Players

Segmentation of Radioligand Therapy Market-

By Biomarker:

  • Prostate-Specific Membrane Antigen
  • Ki 67 Expression and Grading
  • Cytochrome P450 17A1 Inhibitor

By Indications

  • Prostate Cancer
  • Neuroendocrine Tumor (NETs)
  • Others Indications

By Products

  • Approved Products
  • Potential Pipeline

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients